TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04071574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Administration of hCG (10.000IU) for ovulation triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Administration of hCG (10.000IU) for ovulation triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Administration of hCG (10.000IU) for ovulation triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Administration of hCG (10.000IU) for ovulation triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH-A Triptorelin
Description: Administration of Triptorelin (0.1mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH-A Triptorelin
Description: Administration of Triptorelin (0.1mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH-A Triptorelin
Description: Administration of Triptorelin (0.1mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)
Study: NCT04095650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS (Seniors using Technology to Engage in Pain Self-management)
Description: Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
Study: NCT04507685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle (Diet and Exercise)
Description: The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle (Diet and Exercise)
Description: The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week.
Study: NCT01083004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Using indocyanine green as intraoperative dye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brilliant blue arm
Description: Using brilliant blue as intraoperative dye
Study: NCT00715026

Intervention type: DEVICE
Group type: OTHER
Intervention: Trilogy AB Acetabular Hip Implant System
Description: Total hip replacement with ceramic on ceramic treatment surfaces.
Study: NCT01535170

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: bovine Lactoferrin
Description: Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bovine Lactoferrin
Description: Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].
Study: NCT00247000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care in a HF clinic vs Home Telehealth Care for HF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care in a HF clinic vs Home Telehealth Care for HF
Study: NCT00552175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride - 40 mg
Description: duloxetine 40 mg taken orally every day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride - 60 mg
Description: duloxetine 60 mg taken orally every day
Study: NCT00554359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I5NP (a small interfering RNA)
Description: Single IV injection of experimental drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single IV injection of saline
Study: NCT00721474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib fed
Study: NCT05348148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Levocetirizine
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intranasal Mometasone Furoate with oral Levocetirizine
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Study: NCT01179464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminobiphosphonate
Description: Patients will receive standard intravenous biphosphonate treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminobiphosphonate
Description: Patients will receive standard intravenous biphosphonate treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg once daily
Study: NCT02734160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV
Study: NCT03506035

Intervention type: DIAGNOSTIC_TEST
Intervention: Research new biomarker for RA
Description: Analyze T and B cell response against new citrullinated peptides

Intervention type: DIAGNOSTIC_TEST
Intervention: Research new biomarker for RA
Description: Analyze T and B cell response against new citrullinated peptides

Intervention type: DIAGNOSTIC_TEST
Intervention: Research new biomarker for RA
Description: Analyze T and B cell response against new citrullinated peptides
Study: NCT00842738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation
Description: Mindfulness meditation

Intervention type: OTHER
Group type: OTHER
Intervention: No meditation
Description: Health care services as usual

Intervention type: OTHER
Group type: OTHER
Intervention: Controls
Description: No intervention
Study: NCT00202787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-4+cetuximab
Description: Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX-4
Description: FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
Study: NCT03624699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaukos iStent inject®
Description: iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
Study: NCT00822757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V710
Description: Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
Study: NCT00868777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus grafting using allogenic bone
Description: Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
Study: NCT04135339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric exercise.
Description: The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise.
Description: The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
Study: NCT04327687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Description: 5 cycles of 5 minutes of upper limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual sphygmomanometer applied to the upper arm and activated to go through 5 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg. RIC will be completed 1-2 times per day for six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy
Study: NCT02833012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caprylic Triglyceride Oil
Description: 10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caprylic Triglyceride Oil
Description: 10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caprylic Triglyceride Oil
Description: 10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caprylic Triglyceride Oil
Description: 10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: 60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: 60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: 60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: 60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axona
Description: 40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axona
Description: 40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axona
Description: 40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axona
Description: 40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
Study: NCT03568591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosensory Therapy
Description: Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
Study: NCT00320008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop smoking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stop smoking

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose lowering therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose lowering therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure lowering therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid lowering therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid lowering therapy
Study: NCT00708500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (SCH 503034)
Description: Boceprevir, 200 mg capsules, 800 mg TID PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (SCH 503034)
Description: Boceprevir, 200 mg capsules, 800 mg TID PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (SCH 54031)
Description: PEG2b 1.5 μg/kg/week subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (SCH 54031)
Description: PEG2b 1.5 μg/kg/week subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon alfa-2b (SCH 54031)
Description: PEG2b 1.5 μg/kg/week subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir placebo
Description: Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Boceprevir placebo
Description: Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
Study: NCT03583151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic fluid injection
Description: Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection
Description: Solu-medrol
Study: NCT03641872

Intervention type: OTHER
Intervention: Standary therapy
Description: Standary therapy for chronic liver disease with ALI and/or AD
Study: NCT04756700

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DigiCog (BCCAMS app)
Description: Administered as specified in the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DigiCog (BCCAMS app)
Description: Administered as specified in the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Konectom Application
Description: Administered as specified in the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Konectom Application
Description: Administered as specified in the treatment arm.
Study: NCT03120221

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample for iodine measurement
Description: Women will be required to give a urine sample for iodine measurement
Study: NCT04493021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System